Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 15 EU countries

Learn more

White Paper: Market access for in-vitro diagnostic tests in Europe

Get insights from MTRC White Papers to advance your understanding of European market access for IVD tests

Request free of charge
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Methodological review reveals essential gaps and inconsistencies in clinical claims, effects, and outcomes in HTA reviews of diagnostic tests

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. 

In a recent publication, Dinnes et al. conducted a methodological review of 45 HTAs (50 review questions) of diagnostic tests to assess how clearly clinical pathways, test claims, and outcomes are specified within existing HTAs. Although 98% of HTAs described the clinical pathway, only 56% clearly articulated clinical claims, and in 54% at least one test effect mechanism could not be linked to prespecified outcomes. Moreover, 82% of HTAs reported outcomes that were not aligned with stated claims. These methodological gaps and inconsistencies risk under- or overestimating the true value of diagnostic technologies, highlighting the need for standardized tools to systematically define clinical pathways, test claims, and outcomes.

Access the full-text article here.